[HTML][HTML] Antigen-specific immune responses and clinical outcome after vaccination with glioma-associated antigen peptides and polyinosinic-polycytidylic acid …
IF Pollack, RI Jakacki, LH Butterfield… - Journal of Clinical …, 2014 - ncbi.nlm.nih.gov
IF Pollack, RI Jakacki, LH Butterfield, RL Hamilton, A Panigrahy, DM Potter, AK Connelly…
Journal of Clinical Oncology, 2014•ncbi.nlm.nih.govPurpose Diffuse brainstem gliomas (BSGs) and other high-grade gliomas (HGGs) of
childhood carry a dismal prognosis despite current treatments, and new therapies are
needed. Having identified a series of glioma-associated antigens (GAAs) commonly
overexpressed in pediatric gliomas, we initiated a pilot study of subcutaneous vaccinations
with GAA epitope peptides in HLA-A2–positive children with newly diagnosed BSG and
HGG.
childhood carry a dismal prognosis despite current treatments, and new therapies are
needed. Having identified a series of glioma-associated antigens (GAAs) commonly
overexpressed in pediatric gliomas, we initiated a pilot study of subcutaneous vaccinations
with GAA epitope peptides in HLA-A2–positive children with newly diagnosed BSG and
HGG.
Abstract
Purpose
Diffuse brainstem gliomas (BSGs) and other high-grade gliomas (HGGs) of childhood carry a dismal prognosis despite current treatments, and new therapies are needed. Having identified a series of glioma-associated antigens (GAAs) commonly overexpressed in pediatric gliomas, we initiated a pilot study of subcutaneous vaccinations with GAA epitope peptides in HLA-A2–positive children with newly diagnosed BSG and HGG.
ncbi.nlm.nih.gov